Akeso Completes Patient Enrollment in P-III (HARMONi-6/AK112-306) Trial of Ivonescimab for Squamous NSCLC
Shots:
- Akeso has completed patient enrollment in the global P-III (HARMONi-6/AK112-306) trial (1/6 P-III trials) assessing ivonescimab + Pt-based CT vs Tevimbra + Pt-based CT to treat 1L squamous NSCLC in China
- Multiple P-III trials are underway, incl. HARMONi-3 (vs Keytruda + CT) in 1L sq- & non-sq NSCLC (led by Summit Therapeutics), plus trials for PD-L1+ HNSCC (vs Keytruda), 1L biliary tract cancer (with CT vs Imfinzi + CT) & 1L pancreatic cancer. sNDA for ivonescimab monotx. in 1L PD-L1+ NSCLC (vs Keytruda) is under priority review in the NMPA
- The P-III trials depicted that ivonescimab provides synergistic anti-tumor effect in sq-NSCLC pts ineligible to receive Avastin due to bleeding risks
Ref: Prnewswire | Image: Akeso
Related News:- China’s NMPA Accepts NDA for Akeso’s Gumokimab to Treat Moderate to Severe Psoriasis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
